Palisade Bio Inc Stock Price, News & Analysis

Palisade Bio announced a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering their lead product candidate, PALI-2108. This patent protects the composition of PALI-2108, an orally administered, colon-specific PDE4 inhibitor prodrug, under development for treating Ulcerative Colitis (UC). In preclinical studies, PALI-2108 demonstrated promising results, reducing disease activity and body weight loss in a UC mouse model. The company plans to commence a Phase 1 human clinical study of PALI-2108 by the end of 2024.

Palisade Bio (Nasdaq: PALI), a biopharmaceutical company, is set to present at the Virtual Investor Pitch Conference on June 17, 2024, at 12:00 PM ET. J.D. Finley, the CEO, will deliver an 'elevator pitch' and outline the company's forthcoming milestones. The event offers investors and interested parties the chance to submit live questions. A live video webcast will be available on the company's website, with a replay accessible for 90 days post-event.

Palisade Bio's lead product, PALI-2108, has shown promising preclinical results for treating Ulcerative Colitis (UC).

Presented at Digestive Disease Week 2024, data indicates that PALI-2108, an orally administered, colon-specific PDE4 inhibitor, is safe, effective, and well-tolerated in mouse models.

It achieved comparable efficacy to apremilast doses, which are intolerable for human use.

Furthermore, PALI-2108 demonstrated significant improvements in disease activity markers and prevented colon length reduction in a dose-dependent manner.

Notably, it exhibited a large therapeutic window and no systemic toxicity in dog models.

The company plans to commence Phase 1 human trials by year-end 2024.

Palisade Bio reported its financial results for Q1 2024 and provided a business update. The company remains on track to commence a Phase 1 clinical study of its lead product, PALI-2108, for treating Ulcerative Colitis (UC) by the end of the year. Financially, Palisade has $11.3 million in cash and recently raised $4 million, ensuring operations can continue until Q1 2025. Net loss increased to $3.5 million from $2.3 million in the same period last year, primarily due to a 78% rise in R&D expenses, driven by costs related to PALI-2108. Key milestones include completing tox studies and nonclinical activities by Q2 and Q3 2024, respectively, and submitting initial IND/CTA in Q3 2024. The company has also formed a strategic collaboration with Strand Life Sciences and has completed significant ex-vivo studies on PALI-2108.

Palisade Bio, Inc. announced the appointment of Margery Fischbein to its Board of Directors. Ms. Fischbein, a veteran in Wall Street and the biotech industry, brings expertise in corporate finance, business development, M&A, licensing, and strategic alliance transactions. Her appointment is expected to enhance Palisade Bio's strategy and pipeline of novel therapeutics, particularly in autoimmune, inflammatory, and fibrotic diseases.

Palisade Bio, Inc. (Nasdaq: PALI) closed a $4 million private placement with an institutional investor for 615,242 shares of common stock, intended for development of PALI-2108 and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent. The company issued unregistered warrants for up to 922,863 shares of common stock with a term of seven years and an exercise price of $6.314 per share.

Palisade Bio, a biopharmaceutical company, is raising $4 million through a private placement offering. The company will issue common stock and warrants to an institutional investor at $6.5015 per share. The net proceeds will be used for working capital and general corporate purposes. The closing is expected around May 6, 2024.

Palisade Bio announced the successful completion of an analysis demonstrating the potent anti-inflammatory effects of PALI-2108 in treating Ulcerative Colitis (UC). The study showed the superior efficacy of PALI-2108 compared to the approved PDE4 inhibitor apremilast, positioning it as a next-generation therapeutic option for inflammatory bowel disease. The company is set to begin Phase 1 human clinical trials before the end of the year, with promising results from the study conducted in collaboration with Paraza Pharma, Inc.